BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
167.93 USD
-0.9 (-0.53%)
Overall BIIB gets a fundamental rating of 6 out of 10. We evaluated BIIB against 533 industry peers in the Biotechnology industry. BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. BIIB has a bad growth rate and is valued cheaply. These ratings would make BIIB suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
BIIB had a positive operating cash flow in the past year.
In the past 5 years BIIB has always been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB has a better Return On Assets (5.51%) than 92.12% of its industry peers.
BIIB's Return On Equity of 8.84% is amongst the best of the industry. BIIB outperforms 92.68% of its industry peers.
BIIB has a Return On Invested Capital of 9.70%. This is amongst the best in the industry. BIIB outperforms 94.56% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 19.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB's Profit Margin of 15.99% is amongst the best of the industry. BIIB outperforms 93.43% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
The Operating Margin of BIIB (28.50%) is better than 96.44% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
With an excellent Gross Margin value of 75.24%, BIIB belongs to the best of the industry, outperforming 83.68% of the companies in the same industry.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
BIIB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BIIB has been reduced compared to a year ago.
2.2 Solvency
BIIB has an Altman-Z score of 3.23. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIIB (3.23) is better than 72.05% of its industry peers.
The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
BIIB has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. BIIB outperforms 93.06% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, BIIB is not doing good in the industry: 70.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.23 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
The Current ratio of BIIB (2.72) is worse than 66.98% of its industry peers.
A Quick Ratio of 2.04 indicates that BIIB has no problem at all paying its short term obligations.
BIIB has a worse Quick ratio (2.04) than 73.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.52% on average over the next years.
The Revenue is expected to decrease by -0.65% on average over the next years.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.03 indicates a reasonable valuation of BIIB.
97.56% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
BIIB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.47.
A Price/Forward Earnings ratio of 10.76 indicates a reasonable valuation of BIIB.
BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.56% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.42, BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.76 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 97.94% of the companies in the same industry.
98.31% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.88 | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BIIB (11/19/2025, 2:58:18 PM)
167.93
-0.9 (-0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change1.97%
Ins Owners0.14%
Ins Owner Change5.21%
Market Cap24.62B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target175.03 (4.23%)
Short Float %3.86%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.06%
PT rev (3m)1.25%
EPS NQ rev (1m)-54.08%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.76 | ||
| P/S | 2.45 | ||
| P/FCF | 10.88 | ||
| P/OCF | 10.03 | ||
| P/B | 1.35 | ||
| P/tB | 10.32 | ||
| EV/EBITDA | 7.39 |
EPS(TTM)16.74
EY9.97%
EPS(NY)15.61
Fwd EY9.3%
FCF(TTM)15.44
FCFY9.19%
OCF(TTM)16.74
OCFY9.97%
SpS68.66
BVpS124.19
TBVpS16.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.16%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.56% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.23 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.41%
Cap/Depr(5y)68.88%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.36%
Profit Quality(5y)121%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.54%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.48%
OCF growth 3Y-7.55%
OCF growth 5Y-16.48%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -5.79% in the next year.